Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is the second most common leukemia of childhood and is associated with high rates of chemotherapy resistance and relapse. Clinical outcomes for children with AML treated with maximally intensive multi-agent chemotherapy lag far behind those of children with the more comm...
Main Authors: | Amy N. Sexauer, Sarah K. Tasian |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-11-01
|
Series: | Frontiers in Pediatrics |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fped.2017.00248/full |
Similar Items
-
Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance
by: Dilana Staudt, et al.
Published: (2018-10-01) -
FLT3 inhibitors in acute myeloid leukemia
by: Mei Wu, et al.
Published: (2018-12-01) -
Clinical use of FLT3 inhibitors in acute myeloid leukemia
by: Sutamtewagul G, et al.
Published: (2018-10-01) -
Targeted Therapy of FLT3 in Treatment of AML—Current Status and Future Directions
by: Caroline Benedicte Nitter Engen, et al.
Published: (2014-12-01) -
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
by: Vanessa E. Kennedy, et al.
Published: (2020-12-01)